Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

Expert Opinion on Investigational Drugs
Eli V Gelfand, Christopher P Cannon

Abstract

Rimonabant is the first selective blocker of the cannabinoid CB1 receptors being developed for the treatment of obesity, tobacco smoking and cardiometabolic risk factors. Following 1 year of treatment, rimonabant 20 mg/day leads to greater weight loss compared with placebo. Therapy with rimonabant is also associated with favourable changes in serum lipids and an improvement in glycaemic control in Type 2 diabetics. At the same dose, rimonabant significantly increases the cigarette smoking quit rates compared with placebo. Rimonabant appears to be generally well tolerated, with primary side effects of mild nausea, diarrhoea, anxiety and depression. As an agent with a novel mechanism of action, rimonabant has the potential to be a useful adjunct to lifestyle modification in the treatment of obesity, metabolic syndrome and cigarette smoking.

References

Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Aug 1, 1974·Journal of Abnormal Psychology·M P Naditch
Feb 1, 1996·American Journal of Respiratory and Critical Care Medicine
Sep 18, 1997·The Journal of Clinical Investigation·D G DeutschL C Moore
Oct 23, 1997·The New England Journal of Medicine·R D HurtP M Sullivan
Aug 5, 1998·British Journal of Pharmacology·S J MacLennanD W Bonhaus
Aug 26, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·K VargaG Kunos
Nov 4, 1998·American Journal of Epidemiology·P O'HaraR Wise
May 20, 1999·European Journal of Pharmacology·J E GallateI S McGregor
Jun 3, 1999·Psychopharmacology·C M Williams, T C Kirkham
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·L HanusE Fride
Mar 4, 2000·The Biochemical Journal·J LiuG Kunos
Jul 7, 2000·The New England Journal of Medicine·M J StampferW C Willett
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Oct 9, 2001·Nature Medicine·T J De VriesA N Schoffelmeer
Nov 13, 2001·British Journal of Pharmacology·N Jamshidi, D A Taylor
Dec 12, 2001·Journal of the American College of Cardiology·J A WagnerG Ertl
Mar 21, 2002·The American Journal of Medicine·Bernard Karnath
Apr 27, 2002·Science·Rachel I Wilson, Roger A Nicoll
Oct 26, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Christine Ravinet TrillouPhilippe Soubrie
Feb 6, 2003·European Journal of Pharmacology·Ester FrideRaphael Mechoulam
Mar 27, 2003·Journal of Cardiovascular Pharmacology·Andreas BonzJens Andreas Wagner
Apr 24, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Nathalie NiederhofferBela Szabo
May 15, 2003·Endocrinology·Christopher J LyonWilla A Hsueh
May 20, 2003·The European Journal of Neuroscience·L FattoreW Fratta
Aug 5, 2003·The Journal of Clinical Investigation·Daniela CotaUberto Pagotto
Oct 29, 2003·Archives of Internal Medicine·Ilan GoldenbergUNKNOWN Bezafibrate Infarction Prevention Study Group
Feb 11, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·C Ravinet TrillouP Soubrié
Apr 16, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kusnandar AnggadiredjaTsuneyuki Yamamoto
Jun 1, 2004·The American Journal of Psychiatry·Herbert Y MeltzerUNKNOWN Meta-Trial Study Group

❮ Previous
Next ❯

Citations

Mar 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fumihiko YasunoRobert B Innis
Nov 6, 2008·World Journal of Gastroenterology : WJG·Anna Parfieniuk, Robert Flisiak
Sep 20, 2006·Pharmacogenomics·Daniel J Müller, James L Kennedy
Dec 3, 2014·Acta Neuropsychiatrica·Livia C M RodriguesAlline Cristina Campos
Mar 15, 2014·World Journal of Gastroenterology : WJG·Albert J Czaja
May 17, 2007·Expert Opinion on Therapeutic Targets·Keith Suckling
Dec 17, 2008·Expert Review of Gastroenterology & Hepatology·Jean Fioramonti, Lionel Bueno
Dec 19, 2008·Expert Review of Gastroenterology & Hepatology·Zahra Ghiassi-Nejad, Scott L Friedman
Aug 31, 2006·Expert Opinion on Emerging Drugs·Robert A Schnoll, Caryn Lerman
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Michael Soyka, Susanne Roesner
Feb 15, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Mar 20, 2012·Pharmacology, Biochemistry, and Behavior·Julie A Marusich, Jenny L Wiley
Mar 17, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·André J Scheen, Nicolas Paquot
Aug 12, 2008·Neuropharmacology·Jason R ClapperDaniele Piomelli
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·André J Scheen
Oct 20, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Regina A Mangieri, Daniele Piomelli
Nov 17, 2006·Journal of Hepatology·Scott L Friedman
Nov 20, 2008·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Arpana AgrawalTatiana Foroud
Nov 27, 2008·Addiction·Arpana AgrawalPamela A F Madden
Feb 24, 2007·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·M A Cawthorne
Aug 23, 2007·Chemistry & Biodiversity·Giulio G Muccioli
Jan 7, 2014·Alimentary Pharmacology & Therapeutics·A J Czaja
Oct 18, 2008·Drug and Alcohol Dependence·Arpana Agrawal, Michael T Lynskey
Mar 30, 2016·Annual Review of Neuroscience·Natalie E Zlebnik, Joseph F Cheer
Oct 19, 2016·Digestive Diseases and Sciences·Aldo J Montano-LozaAlbert J Czaja
Dec 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Nov 2, 2011·Therapeutic Advances in Gastroenterology·Michal Cohen-Naftaly, Scott L Friedman
Jan 25, 2007·Nature Clinical Practice. Cardiovascular Medicine·Daniel J Rader
Dec 9, 2014·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Jana KucerovaHana Kotolova
Oct 11, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Frédérique Dol-GleizesFrançoise Bono
May 16, 2008·Journal of Clinical Psychopharmacology·Michael SoykaUNKNOWN ACTOL Study Investigators
Jun 11, 2008·Current Opinion in Clinical Nutrition and Metabolic Care·André J Scheen, Nicolas Paquot
Mar 18, 2011·The Cochrane Database of Systematic Reviews·Kate Cahill, Michael H Ussher
Jun 22, 2007·Journal of Chemical Information and Modeling·Jian-Zhong ChenXiang-Qun Xie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.